12/18
08:27 am
alzn
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo [Yahoo! Finance]
Medium
Report
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo [Yahoo! Finance]
12/18
08:00 am
alzn
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
Medium
Report
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
12/16
08:08 am
alzn
Alzamend Neuro, Inc. (NASDAQ: ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $35.00 to $32.00. They now have a "buy" rating on the stock.
Neutral
Report
Alzamend Neuro, Inc. (NASDAQ: ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $35.00 to $32.00. They now have a "buy" rating on the stock.
12/12
08:17 am
alzn
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs [Yahoo! Finance]
Medium
Report
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs [Yahoo! Finance]
12/12
08:00 am
alzn
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Low
Report
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
11/19
08:20 am
alzn
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice [Yahoo! Finance]
Medium
Report
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice [Yahoo! Finance]
11/19
08:00 am
alzn
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
Low
Report
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
11/19
07:36 am
alzn
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential [Yahoo! Finance]
Medium
Report
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential [Yahoo! Finance]
11/11
08:10 am
alzn
Alzamend Neuro, Inc. (NASDAQ: ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $50.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
Alzamend Neuro, Inc. (NASDAQ: ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $50.00 to $35.00. They now have a "buy" rating on the stock.
10/16
08:00 am
alzn
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Medium
Report
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
10/16
07:35 am
alzn
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's [Yahoo! Finance]
Medium
Report
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's [Yahoo! Finance]
10/15
08:15 am
alzn
Alzamend Neuro regains compliance with Nasdaq [Seeking Alpha]
Low
Report
Alzamend Neuro regains compliance with Nasdaq [Seeking Alpha]
10/15
08:00 am
alzn
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
Medium
Report
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
10/10
08:00 am
alzn
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
Low
Report
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference